Log in with your email address username.


[Comment] Rituximab as first-line treatment of pemphigus

Pemphigus is a rare, life-threatening autoimmune blistering disorder with an incidence of one to seven new cases per million inhabitants per year in Europe and the USA. The two major pemphigus subtypes—pemphigus vulgaris and pemphigus foliaceus—account for about 75% and 20% of cases, respectively.